A 62-year-old woman presented with nephrotic syndrome, monoclonal gammopathy, and membranous-like nephropathy with nonorganized deposits composed of monoisotypic immunoglobulin G1 lambda protein. Nephrotic syndrome remitted after a brief course of treatment with melphalan despite ongoing production of the monoclonal protein. The circulating monoclonal immunoglobulin G1 lambda showed unusual in vitro aggregation properties, including dependence on low ionic strength and neutral pH, suggesting that electrostatic interactions had a role in the precipitation process. This case illustrates the importance of looking for monoclonal immunoglobulin deposits when kidney biopsy findings are suggestive of membranous nephropathy. In addition, our in vitro demonstrations of the role of physicochemical factors in immunoglobulin precipitation help elucidate the pathogenesis of immunoglobulin deposition disorders. Although binding to podocyte antigens is a well-recognized determinant of subepithelial immunoglobulin deposition, proneness to aggregation as described in this case also might be nephritogenic.

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.ajkd.2010.03.010DOI Listing

Publication Analysis

Top Keywords

immunoglobulin deposition
12
monoclonal immunoglobulin
12
immunoglobulin
8
circulating monoclonal
8
aggregation properties
8
nephrotic syndrome
8
immunoglobulin lambda
8
monoclonal
5
deposition disease
4
disease membranous
4

Similar Publications

This is a retrospective cross-sectional diagnostic test accuracy study of direct immunofluorescence (DIF) performed on a group of potential lupus erythematosus (LE)/dermatomyositis (DM) skin biopsies from 2015 to 2020 at a large, academic medical center. For purposes of this study, which was focused primarily on detection of LE/DM-related interface dermatitis, DIF was considered positive for a LE/DM pattern if it showed granular deposition of immunoglobulin G, with or without C3, at the basement membrane zone on the final pathology report. Blinded clinicopathologic correlation was the reference standard.

View Article and Find Full Text PDF

Public Health.

Alzheimers Dement

December 2024

MRC Unit for Lifelong Health & Ageing at UCL, London, United Kingdom.

Background: Associations of common infections with Alzheimer's disease have been reported, but potential mechanisms underlying these relationships are unclear. A hypothesised mechanism is amyloid-beta (Aβ) aggregation as a defense mechanism in response to infection, with subsequent tau accumulation. However, no studies have assessed associations of infections with cerebral Aβ and tau pathology in vivo.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Biomarkers, F. Hoffmann-La Roche Ltd., Basel, Switzerland.

Background: Amyloid PET imaging enables the simultaneous assessment of both perfusion and amyloid deposition in people with Alzheimer's Disease (AD) in a single procedure. Perfusion can be derived from kinetic modeling of the full dynamic PET acquisition (i.e.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

Neuro-Sys, Gardanne, France.

Background: Alzheimer's disease (AD) is characterized by the extracellular accumulation of senile plaques composed of beta-amyloid (Aβ) and the intracellular deposition of neurofibrillary tangles composed of hyperphosphorylated tau (Tp). Aβ induces a chronic neuroinflammation that contributes to the neurite network disorganization and finally neuronal death. Lecanemab, a humanized monoclonal antibody (Ab) that recognizes protofibrils/oligomers and prevents Aβ deposition, is the first US approved Ab for AD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!